Novo Nordisk A/S (NYSE:NVO)
$ 134.66 1.74 (1.31%) Market Cap: 599.89 Bil Enterprise Value: 602.45 Bil PE Ratio: 46.60 PB Ratio: 41.56 GF Score: 92/100

Novo Nordisk A/S at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 11:30PM GMT
Release Date Price: $29.79 (+1.03%)
Richard Vosser
JP Morgan Chase & Co, Research Division - Senior Analyst

Welcome to the Novo presentation at the JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to welcome from Novo Mads Krogsgaard Thomsen, Chief Scientific Officer; and Marcus Schindler, SVP of Global Drug Development (sic) [Discovery], to present to you.

Just before I hand over to Mads, after the presentation, the breakout is in the Georgian Room, which is just on the right-hand side. Mads, welcome to the conference.

Mads Krogsgaard Thomsen;S;Executive VP;Chief Science Officer
Novo Nordisk A

/-&

Thank you, Richard. It's a great pleasure to be back at the JPMorgan. Many years ago, we were here, and now we're back. So Marcus will take the more scientific parts towards the end of the presentation. But what I'll share with you is with a great focus on the R&D elements of the company, what we're all about.

So these are the forward-looking statements. As a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot